l-,-D-Arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) and E-5-(2-bromovinyl)uracil, a metabolite of BV-araU, did not affect either the anti-human immunodeficiency virus activity or the cytotoxicity of azidothymidine in MT-4 and MOLT-4 cells. Similarly, the bromovinyl compounds did not affect the in vitro antitumor activities of arabinosylcytosine, 5-fluorouracil, and 5-fluoro-2'-deoxyuridine. The anti-varicellazoster virus activity of BV-araU was not influenced by azidothymidine, 2',3'-didehydro-2',3'-dideoxythymidine, or arabinosylcytosine, whereas relatively high concentrations of fluorinated antitumor agents enhanced the anti-varicella-zoster virus activity.
1--D-Arabinofuranosyl-E-5-(2-bromovinyl)uracil (BVaraU) (12) has potent activity against varicella-zoster virus (VZV) in vitro (9, 10) and low toxicity, including hematological effects, in animals (14, 21, 22) . The clinical effectiveness of oral BV-araU for the treatment of zoster in both immunocompetent and immunocompromised patients have been demonstrated in Japan (7, 15) . Since VZV infections occur more often and may become severe or recurrent in immunocompromised patients, particularly those with cancer (13) or AIDS (4), coadministration with BV-araU and anticancer drugs or anti-human immunodeficiency virus type 1 (HIV-1) agents may be necessary. Consequently, it is important to study the effects of BV-araU in combination with anti-HIV-1 or anticancer agents on the pharmacodynamic activities of BV-araU and the other agents.
E-5-(2-Bromovinyl)uracil (BV-uracil), the single major metabolite of BV-araU (1, 16, 17) , was prepared from BV-araU by cleavage of the N-glycosidic bond according to an oxidation procedure (18) . The BV-araU and BV-uracil preparations were 99.9 and 99.6% pure, respectively, when determined by high-performance liquid chromatography.
3'-Azido-3'-deoxythymidine (AZT) and 1-p-D-arabinofuranosylcytosine (araC) were commercial products of Yamasa Shoyu Co., Ltd. 2' ,3'-Didehydro-2' ,3'-dideoxythymidine (D4T) (2, 6, 8) nation of the cytotoxicity of AZT, and the 50% inhibitory dose (ID50) was obtained in the same manner by using mock-infected cells. As shown in Table 1 , the anti-HIV-1 activity of AZT was influenced minimally by either BV-araU (2.86 and 14.3 ,uM) or BV-uracil (2.31 and 11.5 ,uM). Furthermore, BV-araU did not affect the cytotoxicity of AZT for these cell lines. The selectivity index (ID5JED50) for the anti-HIV-1 activity of AZT in MT-4 and MOLT-4 cells ranged between 880 and 1,600 and between 31,000 and 34,000, respectively, both in the absence and in the presence of BV-araU and BV-uracil.
For the in vitro antitumor activity test, a cell suspension containing 1.1 x 105 human T-cell acute lymphoblastoid leukemia cells (CCRF-HSB-2} per ml was prepared in a growth medium from exponentially growing cells. Cells were incubated with test drug in a 5% CO2 incubator for 4 days at 37°C. The number of cells was counted with a Microcell Counter (Sysmex; type F-300), and the ID50 of the test compound was determined by interpolation from dose-inhibition response curves. The ID50 for L5178Y murine leukemia cells was also determined for some drug combinations by the same manner, except that the cell suspension was prepared at 1.4 x i05 cells per ml and incubated in a 2% CO2 Fig. 1) . The ID50s of araC in the absence and in the presence of 28.6 puM BV-araU and 11.5 p.M BV-uracil were 33, 28, and 25 nM, respectively. The values of 5-FU were 25, 26, and 24 pM,'respectively, and those of FUdR were 9.9, 8.9, and8.0 ,uM, respectively. No effects on the antiproliferative activities ofthese drugs were Ifound by using a murine leukemia cell line (data not shown). The ID Os of araC and 5-FU for L5178Y cells were 1.6 and 3.2 ,uM, respectively, and those in the presence of 28.6 ,uM BV-araU were 1.6 and 3.0 FLM, respectively.
Anti-VZV potency of BV-araU was determined as described previously (9, 10 (11, 20) . dThd reduced the anti-VZV potency of BV-araU at higher concentrations but not lower (Table 2) . Though BV-araU is a dThd analog, VZV plaque was almost completely suppressed by about'3 ,uM BV-araU even in the presence 100 ,uM dThd. This contrasted with the finding on anti-HSV-l activity of BV-araU, which was nullified with 100 ,uM dThd (11) .
The present study found no important in vitro interactions between AZT, D4T, or araC and BV-araU or BV-uracil in regard to antiviral and antitumor activities. 5-FU (10 ,uM) and FUdR (1 p.M) enhanced the anti-VZV activity of BVaraU. However, these concentrations were much higher than drug concentrations in'blood in humans during chemotherapy, and BV-uracil did not show a similar interaction. BV-uracil strongly affects pyrimidine metabolic degradation and results in enhancement of the in vivo antileukemic activity and toxic effects of 5-FU and FUdR (5) . Such enhancing activity was also reported with E-5-(2-bromovinyl)-2'-deoxyuridine (5). Relatively low levels of BV-uracil have been detected in the blood and urine of humans after oral administration of J3V-araU (17) . However, these in vitro studies cannot be used to determine whether BV-araU can be safely coadministered with fluorinated anticancer drugs. On the other hand, since it has been shown in acute and repeat-dose animal studies that no enhancement of toxicity occurs when AZT and BV-araU are given in combination (4a), BV-araU can probably be safely coadministered with AZT.
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